

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 May 2001 (25.05.2001)


PCT

(10) International Publication Number  
**WO 01/36029 A1**

- (51) International Patent Classification<sup>7</sup>: A61M 5/315, 5/32 (74) Agents: BRAINARD, Charles, R. et al.; Kenyon & Kenyon, Suite 700, 1500 K Street, N.W., Washington, DC 20005 (US).
- (21) International Application Number: PCT/US00/28142
- (22) International Filing Date: 12 October 2000 (12.10.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/432,579 12 November 1999 (12.11.1999) US
- (71) Applicant: SCIMED LIFE SYSTEMS, INC. [US/US];  
One SciMed Place, Maple Grove, MN 55311-1566 (US).
- (72) Inventor: ADAMS, Ronald, David; 18 Hillside Drive,  
Holliston, MA 01746 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: METHOD AND APPARATUS FOR DELIVERY OF CONTROLLED DOSES OF THERAPEUTIC DRUGS IN ENDOLUMINAL PROCEDURES



(57) Abstract: An improved method and apparatus (260) for administering drugs during an endoluminal procedure is disclosed. An embodiment of the present invention utilizes a catheter (170) having distal and proximal ends and a drug reservoir (230) located within the catheter (170) to efficiently and accurately deliver drugs during an endoluminal procedure.

WO 01/36029 A1



**Published:**

— With international search report.

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## METHOD AND APPARATUS FOR DELIVERY OF CONTROLLED DOSES OF THERAPEUTIC DRUGS IN ENDOLUMINAL PROCEDURES

### FIELD OF THE INVENTION

5           This invention generally relates to endoluminal procedures. More specifically it relates to an improved method and apparatus for providing accurate, easy to administer, minimum waste delivery of therapeutic drugs while performing endoluminal procedures.

### 10   BACKGROUND

          An endoluminal procedure is a medical procedure that takes place in one of the many lumens within the human body. An endoluminal procedure may take place in vascular, gastrointestinal, or air exchange lumens, and may involve disease diagnosis, or treatment, or both. Millions of endoluminal procedures are performed  
15 each year in hospitals around the world.

          Endoluminal procedures are often performed utilizing a device known as an endoscope. With reference to Fig. 1, an endoscope 140 is a tube, either rigid or flexible, which is introduced into the body lumen 180 through an opening in the human body 185, such as the mouth or rectum. The endoscope may simply be used  
20 to hold open the lumen for examination or it can and usually will contain an open or "working" channel 130 into which the Endoscopist will insert and withdraw a myriad of endoluminal devices. Lights, visionary systems, and other devices may

be incorporated into or used in conjunction with the endoscope to assist in completing the endoluminal procedure.

A treatment device that is commonly used during the completion of endoluminal procedures is a catheter. As illustrated in Fig. 1, the catheter 170 is essentially a flexible hollow tube. Often the catheter is fitted with a hypodermic needle 120 fitted to its distal end for the injection of therapeutic or diagnostic agents. In certain applications, where therapeutic drugs are to be passed into the body lumen 180, the catheter 170 will accept, or be manufactured with, a syringe 150 at its proximal end. The syringe 150 can be pre-filled with a therapeutic drug 195 or it can be filled at some other time, for example, contemporaneous with the endoluminal procedure being performed.

The endoscope 140 will be positioned to allow access to the treatment area 110. Then, as required, the Endoscopist will position the distal end of the catheter through the endoscope into the treatment area 110. The positioning of the catheter is often a difficult and time-consuming process as it must be done by the Endoscopist from the proximal end of the endoscope, which may be a hundred or more centimeters from the treatment area. Once the catheter is positioned drugs can be administered or some other procedure can be performed. Administering the drugs can be an arduous task due to the tremendous pressure required to be applied to the handle 165 to force the drug out of the syringe 150, through the entire length of the catheter 170 and ultimately out the hypodermic needle 120. This is particularly true when the therapeutic drug to be administered is highly viscous.

This method is highly inefficient as the entire internal channel 190 of the catheter 170 must be filled with the drug before even a small amount can be forced into the treatment area 110. Moreover, since the entire internal channel 190 of the catheter 170 will be filled with the drug, a large amount of the drug is simply disposed of, along with the catheter, at the completion of the procedure. This unwanted disposal of therapeutic drugs can be expensive and can add significant cost to the procedure.

Thus, it would be desirable to provide an apparatus that can accurately

deliver a therapeutic drug to an endoluminal treatment site both efficiently and with a minimum of effort and waste.

### SUMMARY OF THE INVENTION

5           The present invention is an improved method and apparatus for administering drugs during an endoluminal procedure that includes a catheter having a distal end and a proximal end and a drug reservoir located within the catheter to efficiently and accurately deliver drugs during an endoluminal procedure.

10

### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 illustrates a known drug delivery device wherein the drug reservoir is located at the proximal end of the catheter.

Fig. 2 illustrates a catheter, in accordance with an embodiment of the  
15 present invention, as it would appear having been introduced into a lumen of the body through the working channel of an endoscope.

Fig. 3 illustrates the distal end of the catheter of Fig. 2 in accordance with an embodiment of the present invention.

Fig. 4 illustrates the embodiment of Fig. 3 without an encasing endoscope or  
20 catheter.

Fig. 5 illustrates an alternative embodiment, without an encasing catheter or endoscope, that utilizes a cable assembly to assist in the delivery of the drug in accordance with the present invention.

Fig. 6A illustrates an alternative embodiment, without an encasing catheter  
25 or endoscope, that utilizes compressed gas to assist in the delivery of the drug in accordance with the present invention.

Fig. 6B illustrates an alternative embodiment, without an encasing catheter or endoscope, that utilizes two reactive chemicals to generate the compressed gas that assists in the delivery of the drug in accordance with the present invention.

30           Fig. 7 illustrates an alternative embodiment of Fig. 6A wherein an injection

nozzle, instead of a hypodermic needle, is utilized to administer the drug.

Fig. 8 illustrates an alternative embodiment of Fig. 7 that employs multiple drug reservoirs manifolded together to a single injection nozzle.

## 5 DETAILED DESCRIPTION

The instant invention provides for an efficient and effective method and apparatus for delivering therapeutic drugs to an endoluminal cavity. Fig. 2 illustrates an embodiment of the drug delivery device 260. As can be seen, the drug delivery device 260 is comprised of a hypodermic needle 120, a connection tube  
10 200, a drug reservoir 230, a flexible catheter 170, an activation line 210, an activation mechanism 280, and an activation mechanism switch 220. The hypodermic needle 120 is rigidly connected to one end of the hollow connection tube 200 and is in fluid communication with the connection tube channel 290 of the hollow connection tube 200. The hollow connection tube 200 is a rigid member  
15 capable of withstanding the bending and kinking forces generated during the insertion, manipulation, and use of the drug delivery device 260 and is generally less than one centimeter in length. The hollow connection tube 200 is rigidly and sealably connected to the cylindrically shaped drug reservoir 230. The exit orifice 270 of the drug reservoir 230 is aligned with, and in fluid communication with, the  
20 connection tube channel 290. An activation mechanism 280 is rigidly connected to the proximal end of the drug reservoir 230 and is in communication with the drugs 195 present in drug reservoir 230. The activation mechanism 280 generates the compressive force necessary to eject drugs 195 from the drug reservoir 230 through the exit orifice 270, through the connection tube channel 290, and out the  
25 hypodermic needle 120. The activation mechanism is connected to a wire 210 which is connected to an activation mechanism control switch 220. The activation mechanism control switch 220 is operated by the Endoscopist and turns the activation mechanism 280 on and off.

The drug 195 in Fig. 2 can be pre-loaded by the drug manufacturer into the  
30 drug reservoir 230 or can be loaded by the Endoscopist at a time contemporaneous

with the procedure. To fill the drug reservoir 230, the Endoscopist would load the drug 195 into the drug reservoir 230 by unscrewing the drug reservoir 230 from the distal end of the catheter 170, filling the drug reservoir 230 with a desired dose of drug 195 through the exit orifice 270 and rescrewing the drug reservoir 230 back  
 5 into the distal end of the catheter 170.

The drug agents used in the present invention include, for example: pharmaceutically active compounds, biologically active solutions, proteins, oligonucleotides, genes, DNA compacting agents, gene/vector systems (*i.e.*, anything that allows for or enhances the uptake and expression of nucleic acids),  
 10 nucleic acids (including, for example, DNA, cDNA, RNA, antisense DNA or RNA), cells (autologous, allogenic, or xenogeneic), and liposomes and cationic polymers that are selected from a number of types depending on the desired application. Examples of the biologically active solutes include: anti-thrombogenic agents such as heparin, heparin derivatives, urokinase, and PPACK  
 15 (dextrophenylalanine proline arginine chloromethylketone); anti-proliferative agents such as paclitaxel, enoxaprin, angiopeptin, or monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid; anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine;  
 20 antineoplastic/antiproliferative/anti-miotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors; anesthetic agents such as lidocaine, bupivacaine, and ropivacaine; anti-coagulants such as D-Phe-Pro-Arg chloromethyl keton, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor  
 25 antagonists, anti-thrombin anticodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides; vascular cell growth promoters such as growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promoters; vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor  
 30 antagonists, transcriptional repressors, translational repressors, replication

inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogeneous vascoactive  
5 mechanisms.

In practicing the invention embodied in Fig. 2 the Endoscopist inserts the endoscope 140 into the patient's body 185 through the opening in the patient's body 185 until the distal end of the endoscope 140 provides access to the lumen 180 to be treated. The distal end of the drug delivery device 260, loaded with the requisite  
10 drug 195, is then guided by the Endoscopist towards the distal end of the endoscope 140 until the hypodermic needle 120 of the drug delivery device 260 reaches the treatment area 110 of the lumen 180. Navigation aides, common in the art, such as lights and optical cameras, typically provided by the endoscope, may be used to aid in the positioning of the distal end of the drug delivery device 260. Once properly-  
15 positioned, the Endoscopist will engage the activation control mechanism 220 thereby sending a signal through the wire 210 to the activation mechanism 280 to instruct the activation mechanism 280 to urge the drug 195, present in the drug reservoir 230, through the hypodermic needle 120, and into the treatment area 110.

Once the drug 195 has been administered into the treatment area 110, the  
20 Endoscopist retracts the drug delivery device 260 from the endoscope 140 and discards the drug delivery device 260.

The activation mechanism 280 may have numerous alternative embodiments as will be evident to those of skill in the art. For example, an electric motor, a cable assembly, or compressed gas could be employed, in conjunction with a moveable  
25 face of the drug reservoir 230, to generate the force necessary to urge the drug 195 from the drug reservoir 230 during the procedure. Alternatively, a collapsible drug reservoir can be employed wherein the compressed gas is used to collapse or implode the drug reservoir 230 in order to squeeze the drug 195 from it as the volume of the drug reservoir 230 decreases.

30 In addition, a specific dosage of a drug can be administered through this



process. For example, the Endoscopist can unscrew the drug reservoir 230 from the distal end of the catheter 170 before the procedure begins and load a specific dosage of a drug 195 into the drug reservoir 230 in order to completely expel it during the procedure. Alternatively, the specific dosage could be pre-measured by the manufacturer and then loaded into the drug reservoir 230 by the manufacturer. Moreover, the activation mechanism 280 could be calibrated in order to eject a predetermined drug dosage from the drug chamber each time the activation mechanism 280 is engaged.

Fig. 3 illustrates an alternative embodiment of a device that can be employed when practicing the present invention. Fig. 3 is an enlarged view of the distal end of the catheter 170. In Fig. 3 the activation mechanism 280 comprises an electric motor 300 having a rotating shaft 340, a gear 360, a connecting member 320, a piston 310, and motor control wires 330. As can be seen, the piston 310 comprises one wall of the cylindrically shaped drug reservoir 230 that is designed to slide within the drug reservoir 230 in order to push the drug 195 through the exit orifice 270 of the drug reservoir 230. The piston 310 is pushed by the connecting member 320. The connecting member 320 is rigid and pole-like with screw threads 370 etched into its outer surface. The electric motor shaft 340 is in contact with a gear 360 that is in communication with the screw threads 370 of the connecting member 320 and causes the connecting member 320 to push the piston 310 towards the drug 195 in the drug reservoir 230 when the electric motor 300 is in operation. The greater the number of rotations completed by the electric motor 300 the greater the distance the piston 310 will travel and the greater the volume of drug 195 will be forced from the drug reservoir 230 and out the hypodermic needle 120.

The electric motor 300 in Fig. 3 is activated by the Endoscopist from the proximal end of the drug delivery device 260. As required, the Endoscopist will energize the motor control wires 330 by depressing the activation mechanism control switch 220 which contains both a depressable on and off button and a common 1.5 volt dc power source such as a Duracell® MS76 silver oxide battery or an Energizer® 357 watch battery. Once activated, the electric motor 300 in Fig. 3

will rotate, ultimately pushing the piston 310 forward into the drug reservoir 230.

Fig. 4 provides an enlarged view of the distal end of the embodiment depicted in Fig. 3 without the endoscope 140 or the encasing catheter 170. As is evident and as was illustrated in Fig. 3, the electric motor 300 has a motor shaft 340 that is in direct rotational communication with a gear 360 that is in direct rotational communication with the screw threads 370 of the connecting member 320. As the electric motor 300 turns it rotates the motor shaft drive 340 that turns the gear 360 which is inscribed with teeth 365 that meet with and advance the screw threads 370 thereby rotating and advancing the connecting member 320. As in Fig. 3, the connecting member 320 advances and pushes the piston 310 further into the drug reservoir 230 thereby forcing any drug 195 present in the drug reservoir 230 out the exit orifice 270, through the connection tube 200, and out the hypodermic needle 120.

Alternatively, instead of using the electric motor assembly described above, a cable assembly system could be used to force the drug 195 from the drug reservoir 230. Fig. 5, which provides an enlarged view of the distal end of the present invention, without the encasing endoscope or catheter, employs such a cable assembly system 500. The cable assembly system shown in Fig. 5 contains a piston 310, a connecting member 320 perpendicularly affixed to the piston 310, a first pulley 520, rotatably attached to the end opposite the piston 310 of the connecting member 320, a second pulley 510, rotatably connected to a support bar 550 that is rigidly connected to the drug reservoir 230, and a cable 540. The cable assembly system, as is evident, also contains a cable 540. One end of the cable 540 is attached to the center of the second pulley 510 with the other end being free and accessible at the proximal end of the drug delivery device. The cable 540 loops around the first pulley 520, around the second pulley 510 and then extends through the drug delivery device 260 until the cable's other end emerges at the device's proximal end for use by the Endoscopist.

As required, the Endoscopist will pull on the loose available end of the cable 540 in order to inject the drugs into the luminal area to be treated. In operation,

when the cable 540 is pulled the first pulley 520 is drawn towards the second pulley 510. Being coupled to the connecting member 320, the first pulley 520 moves the connecting member 320 along with it. As the first pulley 520 moves closer to the second pulley 510, which is rotatably mounted to the support member 550, the  
5 connecting member 320 and the piston 310, connected to the first pulley 520, will also move the same distance. As the piston 310 moves, the drug 195 present in the drug reservoir 230 is urged therefrom and is ultimately forced out the hypodermic needle into the luminal area to be treated. As is evident the cable can be pulled at various rates of speed and for various predetermined distances in order to control  
10 the dosage delivered. Therefore, in practice, the Endoscopist can administer a portion of the drugs present in the drug reservoir or can displace the entire volume of the drug reservoir by varying the length of cable 540 that the Endoscopist pulls from the working end of the drug delivery device 260.

Fig. 6A is a view of the distal end of another embodiment of the present  
15 invention absent the encompassing catheter 170 and the endoscope 140. In this embodiment compressed gas is utilized to move piston 310 instead of an electric motor or cable assembly system. The compressed gas 610 is located within a compressed gas chamber 630 proximate to the piston 310 of the drug reservoir 230 and is used to generate the compressive force required to push the piston 310  
20 against the drug 195 and to force the drug 195 through the exit orifice 270. The compressed gas 610 may be pre-loaded into the compressed gas chamber 630 before the entire drug delivery device 260 is inserted into the patient. Various methods of loading the compressed gas 610 into the compressed gas chamber 630 will be readily apparent to one of skill in the art and can include pre-loading both  
25 the compressed gas 610 and the drug 195 before the procedure is performed at the manufacturing facility, and loading the compressed gas 610 into the compressed gas chamber 630 through a charging orifice 650 contemporaneous with the performance of the procedure.

Alternatively, as can be seen in Fig. 6B, instead of loading compressed gas  
30 into compressed gas chamber 610 the compressed gas chamber may be divided by a

removable partition 660 that separates two reactive chemicals 670 which, when combined, react to create an innocuous compressed gas. Therefore, in practice, before the beginning of the procedure, the Endoscopist will remove the removable partition 660, from the compressed gas chamber, exposing the reactant chemicals to  
5 each other and causing them to react and generate the compressed gas that will be required to eject the drug 195 from the drug reservoir 230.

To prevent the undesired discharge of the drug 195 once the compressed gas chamber is charged a micro-valve 600 is inserted into the connection tube 200. This micro-valve 600 is opened and closed by depressing a plunger 640 located at  
10 the proximal end of the drug delivery device 260 on the proximal end of the valve control line 620, outside the patient's body. The valve control line 620 is in communication with the micro-valve 600. When the plunger 640 is depressed it pushes a cable 660, located within the valve control line 620 that slides the micro-valve 600 open. When the micro-valve 600 is opened the drug 195, under pressure  
15 from the compressed gas 510, can now flow and travel through the micro-valve 600 and out the hypodermic needle 120. Thus, as required during the procedure, the Endoscopist will depress the plunger 640, which opens the micro-valve 600 and permits the compressed gas 610 to push the piston 310 against the drug 195 in order to urge the drug out of the reservoir and ultimately into the treatment area.

20 In an alternative embodiment of the device in Fig. 6A, the drug reservoir 230 is, instead, manufactured as a reconfigurable chamber. Made from a flexible membrane, in lieu of the rigid material depicted above, the reconfigurable chamber collapses from the compressive loads of the compressed gas during use. Rather than pushing the piston 310 to force the drug 195 from the drug reservoir 230 the  
25 compressed gas 610 would act upon the reconfigurable drug reservoir 230 to collapse it and squeeze the drugs from it once the micro-valve 600 is opened.

Fig. 7 is an alternative embodiment of Fig 6A illustrating an injection nozzle 700 being employed for injecting drugs 195 into the treatment area 110 in lieu of a hypodermic needle 120. The injection nozzle, as is known to one of skill in the art,  
30 drives the drug into the tissue.

Fig. 8 illustrates an alternative embodiment of the present invention which employs a plurality of N drug reservoirs at the distal end of the drug delivery device and an injection nozzle 700. As is evident several drug reservoirs 230 and 810 numbered 1...N are connected to a manifold 820 with N input ports 830 and one  
5 output port 840. The output port 840 of the manifold 820 is connected to the injection nozzle 700. Different drugs can be loaded into each of the drug reservoirs to be injected one at a time or in different combinations into the manifold 820 and out the injection nozzle 700 of the drug delivery device. Alternatively, the same drug can be placed within each of the drug reservoirs to increase the dosage  
10 available for the procedure.

As described above, an endoluminal drug delivery method device is provided. The disclosed embodiments are illustrative of the various ways in which the present invention may be practiced. Other embodiments can be implemented by those skilled in the art without departing from the spirit and scope of the present  
15 invention.

CLAIMSWhat is claimed is:

- 1 1. An endoluminal drug delivery device comprising:  
2 a catheter having a distal end and a proximal end; and  
3 a drug reservoir located within said catheter.
- 1 2. The endoluminal drug delivery device of claim 1 wherein said drug  
2 reservoir is located at said distal end of said catheter.
- 1 3. The endoluminal drug delivery device of claim 1 wherein said drug  
2 reservoir is a reconfigurable chamber.
- 1 4. The endoluminal drug delivery device of claim 1 further comprising an  
2 activation mechanism disposed within said drug reservoir.
- 1 5. The endoluminal drug delivery device of claim 4 wherein said activation  
2 mechanism is a piston movable within said drug reservoir.
- 1 6. The endoluminal drug delivery device of claim 5 further comprising:  
2 an electric motor having a rotating shaft drive; and  
3 a connecting member having a first end and a second end with said first end  
4 of said connecting member in communication with said shaft drive of said electric  
5 motor and  
6 said second end of said connecting member in communication with said piston.
- 1 7. The endoluminal drug delivery device of claim 5 further comprising a  
2 compressed gas chamber sealably connected to and in communication with said  
3 piston.

1 8. The endoluminal drug delivery device of claim 7 wherein said compressed  
2 gas chamber contains a removable partition.

1 9. The endoluminal drug delivery device of claim 7 further comprising:  
2 a connection tube having a first end and a second end; and  
3 a micro-valve interposed between said first end and said second end;  
4 wherein said drug reservoir includes an exit orifice and wherein said first  
5 end of said connecting tube is connected to said exit orifice and said second end of  
6 said connecting tube is in fluid communication with said distal end of said catheter.

7 10. The endoluminal drug delivery device of claim 9 further comprising:  
8 a plurality of drug reservoirs wherein each drug reservoir includes a  
9 connecting tube; and  
10 a manifold having a single output port and a plurality of input ports  
11 configured to be in fluid communication with said connecting tube.

1 11. The endoluminal drug delivery device of claim 1 further comprising an  
2 injection nozzle affixed to said distal end of said catheter.

1 12. The endoluminal drug delivery device of claim 1 further comprising a  
2 hypodermic needle affixed to said distal end of said catheter.

1 13. A method of delivering controlled doses of drugs during endoluminal  
2 procedures comprising:  
3 (a) providing a catheter having a distal end and a proximal end;  
4 (b) positioning a drug reservoir within said catheter, said drug reservoir  
5 containing a drug; and  
6 (c) ejecting a predetermined quantity of said drug from said distal end of  
7 said catheter.

1 14. The method of claim 13 wherein step (c) includes the sub-step of:

2 (i) sliding a piston within said reservoir.

1 15. The method of claim 13 wherein said step (c) includes the sub-steps of:

2 (i) positioning an electric motor in communication with a piston  
3 within said catheter;

4 (ii) energizing said electric motor; and

5 (iii) sliding said piston within said reservoir.

1 16. The method of claim 13 wherein step (c) includes the sub-steps of:

2 (i) positioning a micro-valve in fluid communication with said  
3 drug reservoir; and

4 (ii) opening said micro-valve.

1 17. The method of claim 13 further comprising:

2 (d) providing a plurality of drug reservoirs within said catheter;

3 (e) manifolding said drug reservoirs to be in fluid communication with  
4 said distal end of said catheter.

1 18. The method of claim 17 further comprising the step of mounting an

2 injection nozzle to said distal end of said catheter.

1 19. The method of claim 13 further comprising:

2 (d) mounting an injection nozzle to said distal end of said catheter.

1 20. The method of claim 13 wherein step (c) includes the sub-step of:

2 (i) pulling a cable from said distal end of said catheter wherein said  
3 cable is connected to a piston located in said drug reservoir.

1 21. A medical device comprising :



1           a catheter having a distal end and a proximal end;  
2           a drug reservoir at or near said distal end of said catheter; and  
3           a drug located within said drug reservoir.

1   22.   The medical device of claim 21 wherein said drug is selected from the group  
2           consisting of: a biologically active solute, an anti-proliferative, an  
3           anesthetic, and an anti-coagulent.

1/6




FIG. 1  
(PREVIOUSLY KNOWN)

2/6




FIG. 2

3/6




FIG. 3




FIG. 4

4/6




FIG.5

5/6




FIG. 6A




FIG. 6B




FIG. 7




FIG. 8

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 00/28142

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61M5/315 A61M5/32

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)  
EPO-Internal, WPI Data, PAJ, BIOSIS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.     |
|------------|--|---------------------------|
| X          | US 5 840 061 A (MENNE ANDREAS ET AL)<br>24 November 1998 (1998-11-24)<br>column 4, line 30 -column 6, line 54;<br>figures 1-5                        | 1-5, 7, 9,<br>11, 21, 22  |
| X<br>A     | US 4 578 061 A (LEMELSON JEROME H)<br>25 March 1986 (1986-03-25)<br>column 5, line 44 - line 64<br>column 8, line 23 -column 9, line 35;<br>figure 6 | 1-5, 12,<br>21, 22<br>6-8 |
| X<br>A     | US 5 845 646 A (LEMELSON JEROME)<br>8 December 1998 (1998-12-08)<br>column 15, line 31 -column 16, line 5;<br>claims 1-8; figures 12-15              | 1-5, 12,<br>21, 22<br>6   |

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*G\* document member of the same patent family

Date of the actual completion of the international search

29 January 2001

Date of mailing of the international search report

02/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Levert, C



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/28142

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s)  | Publication<br>date  |
|---|---------------------|---|--|
| US 5840061 A                              | 24-11-1998          | DE 29507987 U<br>AT 176872 T<br>AU 705052 B<br>AU 5897296 A<br>CA 2195219 A<br>DE 59601342 D<br>WO 9636381 A<br>EP 0771219 A<br>ES 2129265 T<br>JP 10513391 T | 19-09-1996<br>15-03-1999<br>13-05-1999<br>29-11-1996<br>21-11-1996<br>01-04-1999<br>21-11-1996<br>07-05-1997<br>01-06-1999<br>22-12-1998 |
| US 4578061 A                              | 25-03-1986          | US 4588395 A<br>US 5993378 A<br>US 4900303 A<br>US 4803992 A  | 13-05-1986<br>30-11-1999<br>13-02-1990<br>14-02-1989   |
| US 5845646 A                              | 08-12-1998          | US 6058323 A  | 02-05-2000   |

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**